MarketWatch (press release)OPKO Health Announces Publication of Study Detecting Antibodies in NMO …MarketWatch (press release)MIAMI, Apr 05, 2013 (BUSINESS WIRE) — OPKO Health, Inc. (NYSE:OPK) today announced the publication of a study applying its …
Detecting chronic kidney disease in population-based administrative databases … – 7thSpace Interactive (press release)
Detecting chronic kidney disease in population-based administrative databases …7thSpace Interactive (press release)Large, population-based administrative healthcare databases can be used to identify patients with chronic kidney disease (CKD) when ser…
Actress Asal Badiei passes away at 36 – Tehran Times
|
Actress Asal Badiei passes away at 36
Tehran Times TEHRAN — Actress Asal Badiei has died at the age of 36 at Tehran’s Loqman Hospital. She was admitted to the hospital on March 31 allegedly for drug poisoning, which led to her brain death a day later, the Persian news outlets announced last week. |
Abnormal BP Raises Delayed Graft Function Risk – Renal and Urology News
|
Abnormal BP Raises Delayed Graft Function Risk
Renal and Urology News Other risk factors for DGF included longer cold ischemia time, older donor age, and receipt of a kidney from a donor after cardiac death. Dr. Kumar’s group observed that optimal BP management soon after kidney transplantation has not been well studied. |
Biogen Idec Inc. (NASDAQ:BIIB) Jumps over 34% in 3 Months As Positive MS … – Galaxy Stocks
Galaxy StocksBiogen Idec Inc. (NASDAQ:BIIB) Jumps over 34% in 3 Months As Positive MS …Galaxy StocksShares of Biogen Idec Inc. (NASDAQ:BIIB) got a raise in the opening minutes of trading on Thursday following the firm declared results from its multip…
Obese Young Adults Are At Risk For Chronic Kidney Disease – KREX News Channel 5
Times of IndiaObese Young Adults Are At Risk For Chronic Kidney DiseaseKREX News Channel 5A new British study finds people who gain excess weight in their 20s and 30s are twice as likely to develop chronic kidney disease in their 60s. Researchers also …
RPT-BRIEF-Emergent Biosolutions to expand clinical trial of TRU-016 and … – Reuters
RPT-BRIEF-Emergent Biosolutions to expand clinical trial of TRU-016 and …ReutersApril 5 (Reuters) – April 5 (Reuters) – Emergent Biosolutions Inc : * To expand front line CLL clinical trial of TRU-016 and rituximab based on strong patient enrollment …
Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and … – Fort Mills Times
Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and …Fort Mills TimesEmergent BioSolutions Inc. (NYSE: EBS) today announced its decision to expand the protocol for its ongoing Phase 1b, single arm, open label study (Protocol …
Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and … – MarketWatch (press release)
|
Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and …
MarketWatch (press release) “Emergent is pleased with the progress of our Phase 1b study of TRU-016 in combination with rituximab in front line patients with CLL. The strong enrollment and the encouraging early data from this open label study are expected to facilitate an … |
Organ donation registration event planned for April 27 – Herald Palladium (subscription)
Organ donation registration event planned for April 27Herald Palladium (subscription)Organ donation registration event planned for April 27. Story · Comments. Print: Create a hardcopy of this page; Font Size: Default font size: Larger font size….